Therapeutic Vaccination for HPV-Mediated Cancers

Abstract

Purpose of Review

The goal of this narrative review is to educate clinicians regarding the foundational concepts, efficacy, and future directions of therapeutic vaccines for human papillomavirus (HPV)–mediated cancers.

Recent Findings

Therapeutic HPV vaccines deliver tumor antigens to stimulate an immune response to eliminate tumor cells. Vaccine antigen delivery platforms are diverse and include DNA, RNA, peptides, proteins, viral vectors, microbial vectors, and antigen-presenting cells. Randomized, controlled trials have demonstrated that therapeutic HPV vaccines are efficacious in patients with cervical intraepithelial neoplasia. In patients with HPV-mediated malignancies, evidence of efficacy is limited. However, numerous ongoing studies evaluating updated therapeutic HPV vaccines in combination with immune checkpoint inhibition and other therapies exhibit significant promise.

Summary

Therapeutic vaccines for HPV-mediated malignancies retain a strong biological rationale, despite their limited efficacy to date. Investigators anticipate they will be most effectively used in combination with other regimens, such as immune checkpoint inhibition.

Introduction

Human papillomavirus (HPV)–mediated cancers are common, and result in substantial morbidity and mortality. HPV causes 690,000 cancers of the cervix, oropharynx, anus, vulva, vagina, and penis annually, accounting for 5% of all cancers worldwide [1, 2]. Globally, cervical cancer is the most prevalent, and also the most fatal, HPV-mediated cancer [3]. Over 310,000 patients die of this disease each year [3]. In the USA, HPV-mediated oropharyngeal cancer (HPV + OPC) is the most common HPV-mediated cancer. Here, more than one-third of HPV + OPC patients have stage II–IV disease with 4-year overall survival (OS) rates ranging from 20 to 77% [4].

Treatment of HPV-mediated cancers is also toxic. In the USA, 85% of HPV + OPC patients require multimodal therapy involving primary surgery ± radiation ± chemotherapy or primary radiation ± chemotherapy[4]. Many develop subsequent xerostomia and dysphagia [5], and a minority experience long-term gastrostomy-tube dependence, osteoradionecrosis, and even treatment-related death [6–8].

Therefore, novel treatment options are required for patients with HPV-mediated malignancies. In the HPV + OPC population, deintensification trials to reduce patient morbidity continue to apply bi- and tri-modality treatment strategies, albeit at reduced doses [9–11]. Targeted biologic therapies, such as cetuximab, have exhibited limited efficacy in HPV-mediated cancers to date [12, 13]. Primary head and neck cancer (HNC) patients who received definitive treatment intensification with immune checkpoint inhibition did not experience improved oncologic outcomes [14]. In patients with recurrent or metastatic cervical cancer and HNC, immune checkpoint inhibitors (ICIs) only modestly prolonged overall or progression-free survival and only confer durable responses in a minority of patients [15–17].

Therapeutic vaccination is an experimental therapy for patients with HPV-mediated malignancies, and has the potential to help close this gap in care. Although early results have been underwhelming [18], promising trials pairing vaccines with novel adjuvants, other vaccines, ICIs, or other therapies are currently underway.

This narrative review focuses exclusively on therapeutic vaccines that leverage HPV-specific antigens, rather than HPV-agnostic therapeutic vaccines. This study has two primary objectives. First, we aimed to “prime” clinicians regarding foundational concepts in therapeutic cancer vaccination. Second, we aimed to recapitulate the evidence regarding the clinical efficacy of therapeutic vaccination in patients with HPV-mediated (pre)malignancies. As the target readers are clinicians, preclinical trials and trials evaluating immune response data alone are not discussed.

Foundational Concepts of Therapeutic Cancer Vaccines

Definition

In the context of cancer, therapeutic vaccination is a type of immunotherapy that delivers tumor antigens to the immune system to stimulate an immune response to eliminate tumor cells.

Within the broad category of cancer immunotherapy, therapeutic vaccination is distinguished by the nature in which it produces an immune response—via tumor antigen. This type of immunotherapy is distinct from others, including the following:

• Oncolytic virus therapy (e.g., talimogene laherparepvec [T-vec]),

• Targeted biologic therapy (e.g., cetuximab: IgG1 epidermal growth factor receptor [EGFR] monoclonal antibody),

• ICIs (e.g., monoclonal antibodies to PD-1, PD-L1, and CTLA-4),

• Cytokine therapies (e.g., interleukin-2 [IL-2], interferon-α [IFN-α]), and

• Adoptive cell transfer (e.g., T cell receptor [TCR]–engineered T cell therapy) [19, 20].

The definition of therapeutic vaccination is further clarified by discussing its similarities and differences with other selected immunotherapies. Neither T-vec, bacillus Calmette-Guérin (BCG), nor adoptive cell transfer (ACT) therapy directly uses tumor antigen to induce an immune response. Talimogene laherparepvec is a recombinant, oncolytic herpes simplex virus [HSV]-1 encoding GM-CSF approved for local intratumoral treatment of unresectable, recurrent, metastatic melanoma [21, 22]. The therapy indirectly releases tumor antigens through viral-mediated tumor oncolysis. BCG is an attenuated, live strain of Mycobacterium bovis that is approved for treatment and prophylaxis of urinary bladder carcinoma in situ (CIS) and recurrent early-stage papillary tumors after transurethral resection [23]. The BCG live cancer vaccine stimulates the release of chemokines and cytokines, which activate an unspecified adaptive immune response [23]. Although controversial, we argue this is not a therapeutic cancer vaccine, as traditionally defined, because the vaccine does not include known, tumor-specific antigens.

In adoptive cell transfer (ACT) therapy, immune effector cells are activated independent of antigen delivery. Examples of ACT therapy include tumor-infiltrating lymphocyte (TIL)–based ACT therapy, and TCR-engineered T cell therapy, of which chimeric antigen receptor (CAR) T cell therapy is a type [19, 20]. CAR T cell therapy involves leukapheresis, genetically engineering autologous T cells to express CARs ex vivo, expansion, and reinfusion into patients. CARs bypass the MHC system and engraft T cells with predefined specificity towards a target antigen, facilitating improved affinity for, and elimination of, tumor cells [19, 24]. ACT therapy targeting HPV-16 E7 is promising. In a first-in-human, phase I trial in 12 patients with metastatic HPV16 + cancers after failed systemic treatment, the overall response rate was 50% [25].

Key Components and Considerations

Successful therapeutic vaccines consist of effective tumor antigens, antigen delivery platforms, adjuvant, and delivery vehicles [26]. We address the former three topics in this review. Many other features of these vaccines must be considered, and these are briefly discussed below.

Tumor Antigens

There are two primary categories of tumor antigens: tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs) [27]. TAAs are self-antigens that are abnormally expressed by the tumor [27]. Since they are not entirely tumor-specific, TAAs are subject to tolerance mechanisms which must be overcome to elicit an immune response [27]. Hence, vaccines targeting TAAs also risk induction of autoimmunity. Cancer testis antigen is a quintessential TAA. It is overexpressed in a wide range of tumors, yet among “self” cells, it is only expressed by male germ cells [28]. These cells do not express major histocompatibility complex (MHC) class I molecules and therefore cannot present antigen to T cells [28]. TSAs, on the other hand, are entirely specific to the tumor and not subject to immune tolerance. Oncoviral antigens and neoantigens (generated by mutations in tumor DNA) are examples of TSAs [27, 29].

Antigen Delivery Platforms

There are three broad categories of antigen delivery platforms: molecular, microbial, and cellular. Molecular antigen delivery platforms include small nucleic acids (e.g., DNA, RNA), and peptides or proteins (Fig. 1). Microbial vectors include viruses and, less commonly, bacterial vectors. In addition to expressing tumor antigen(s), microbial vectors themselves are often immunogenic (Fig. 1), thereby leveraging both adaptive and innate immunity. In some cases, microbial vectors are oncolytic.

Fig. 1.

The intended immune response to therapeutic vaccination for HPV-mediated malignancies. The primary goal of therapeutic vaccination for cancers of HPV etiology is to initiate a cytotoxic T cell response against HPV antigens expressed on tumor cells. DC-based vaccines introduce licensed DCs that have undergone licensing and been loaded with antigen ex vivo (center panel). Peptide- or protein-based vaccines introduce peptide/protein in a form for uptake by endogenous DCs, such as a virus-like particles or liposomal carriers (left panel). DNA- and RNA-based vaccines introduce nucleic acids which are then transcribed and translated by recipient cells to produce HPV peptides or proteins (left panel). The nucleic acids can be delivered via DNA plasmids, virus-like particles, viral vectors, or bacterial vectors. The targeted cell type and mechanism of cellular entry vary with the specific vaccine formulation and route of administration. For example, DNA plasmids may be injected intramuscularly, and electroporation can be used to enhance cellular uptake. Viral vectors can enter cells by viral infection pathways. All of these will be taken up by phagocytic cells, but bacterial vectors typically target phagocytes as the cell type in which the antigenic proteins will be produced. Left panel: Antigenic peptides or proteins or DNA/RNA encoding antigenic peptides/proteins are introduced in a formulation and via a route of administration designed to activate the innate immune system and trigger DC licensing. Licensed DCs will upregulate MHCI expression, present antigenic peptides, upregulate costimulatory molecules (B7), and migrate to secondary lymphoid organs, carrying antigen with them. Center panel: In the secondary lymphoid tissues, DCs may interact with CD4 + T helper cells, resulting in a further increase in costimulatory molecule expression. CD4 + T helper cells may also provide T cell help to B cells, enhancing B cell effector functions. Licensed DCs will interact with naïve CD8 + T cells; those with appropriate T cell receptor specificity will be activated. Activated CD8 + T cells will proliferate, acquire their effector function of cytotoxicity, exit the secondary lymphoid tissues, and migrate to sites of inflammation, including tumors. Right panel: Cytotoxic T cells will infiltrate the tumor and kill tumor cells expressing their cognate antigen by releasing cytotoxic molecules that induce apoptosis

Cellular vaccines use whole cells and involve the delivery of tumor antigens to activate an immune response. These primarily consist of two categories: whole tumor cell vaccines and antigen-presenting cell (APC)–based vaccines [27]. In the whole tumor cell vaccine approach, inactive, autologous, or allogeneic tumor cells are co-administered with adjuvant [30]. Given the approach’s limited success in phase III trials, enthusiasm for whole tumor cell vaccination has waned [27, 30].

APC-based vaccination represents the final step in (processed) antigen delivery to immune effector cells, and includes dendritic cell (DC)– and peripheral blood mononuclear cell (PBMC)–based vaccines. A common DC-based vaccine approach involves pulsing autologous DCs ex vivo with cell lysates or tumor antigens and reintroducing the licensed DCs into the patient (Fig. 1). Peripheral blood mononuclear cell (PBMC)–based vaccines are less commonly described, albeit prevalent, APC-based vaccines [31–33]. Some PBMC-based vaccines are mistakenly considered to be DC-based vaccines [31–33]. PBMCs are harvested by leukapheresis and consist of lymphocytes (i.e., T cells, B cells, natural killer cells) and monocytes, which differentiate into macrophages and dendritic cells. This approach leverages the antigen-presenting capacity of a broader spectrum of APCs, including B cells and other monocytes. It bypasses the process of DC isolation, which requires differentiation and maturation from monocytes in PBMCs [34]. Hence, proponents argue it is a simpler, less expensive approach compared to DC-based vaccines [31, 35].

Adjuvant

Therapeutic vaccines often co-administer adjuvant with tumor antigen(s) in order to enhance the “magnitude, breadth, and durability” of the immune response to the antigen(s) [36]. Adjuvants also guide the type(s) of innate, humoral, and cell-mediated immune response to be elicited [37]. For therapeutic cancer vaccines, the ideal adjuvant overcomes the tumor’s immunosuppressive microenvironment and elicits an effective, tumor-specific, CD8 + cytotoxic T cell response.

Adjuvant classification systems are heterogeneous, in part because the mechanisms of their immunogenicity are not fully understood [38]. One system classifies adjuvants on a continuum according to their depot/delivery and immunostimulatory capabilities [39]. Many newer adjuvants possess both traits. A broad definition of the term “adjuvant” is applied in this review and includes components of vaccines that are genetically engineered to express cytokines, chemokines, and costimulatory molecules.

In their landmark study, Singh and Hagan assign adjuvants to the following categories: mineral salts (e.g., aluminum salts), immunostimulators (e.g., cytokines, bacterial products such as lipopolysaccharide [LPS]), lipid particles (e.g., emulsions), microparticulates, and mucosal adjuvants [38]. Aluminum salts and water–oil emulsions are among the most commonly used vaccine adjuvants [36, 39]. The former preferentially induce humoral- over cell-mediated immunity and are used in the bivalent, quadrivalent, and nonavalent prophylactic HPV vaccines. Montanide ISA-51 is a combination of a water–oil emulsion and the surfactant mannide monooleate, and has been incorporated into several therapeutic HPV vaccines [39].

Coffman et al. emphasize the importance of adjuvant selection to shape the type of immune response desired [37]. They classify adjuvants into empirically derived adjuvants (e.g., aluminum salts, Freund’s adjuvant) and adjuvants targeting pattern recognition receptors (PRRs; e.g., toll-like receptor 3 [TLR3] ligands) [37]. Regardless of classification, each adjuvant directs a unique humoral-, cell-mediated, or mixed humoral- and cell-mediated immune response. For example, polyinosinic-polycytidylic acid (poly-IC) activates TLR3 and melanoma differentiation–associated protein 5 (MDA5), which collectively stimulate an antibody, Th1, and CD8 + T cell immune response [37]. In order to further optimize vaccine efficacy, Coffman et al. recommend combining empirically derived adjuvants and PRR ligands to appropriately guide a desired immune response [37].

Other Therapeutic Vaccine Considerations

Investigators and clinicians must consider many other factors in selecting a candidate therapeutic cancer vaccine. The route of therapeutic vaccine administration, dose, and dosing regimen schedule must be optimized [29]. Most vaccines apply a homologous prime-boost approach, where administration of a prime dose is followed by additional boost doses of the same vaccine, usually over a matter of weeks. The time to manufacture the vaccine is also a factor. This is shorter for small nucleic acid–based vaccines and longer for viral vectored and personalized vaccines [29].

Precedent for Therapeutic Cancer Vaccines

Although enthusiasm for therapeutic cancer vaccines is robust, particularly in combination with other therapies, there is limited precedent for the practice. The Federal Drug Administration (FDA) has only approved one therapeutic cancer vaccine, sipuleucel-T. Sipuleucel-T is an autologous PBMC-based vaccine (enriched for a DC fraction) approved for use in asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer patients. PBMCs are pulsed ex vivo with the recombinant protein granulocyte–macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP, which is expressed by prostate cancer cells). In a landmark phase III trial, sipuleucel-T significantly, albeit modestly, improved patient overall survival compared to placebo (median: 4.1 months, 25.8 months versus 21.7 months) [40].

Foundational Concepts in Therapeutic Vaccination for HPV-Mediated Cancers

HPV Epidemiology

HPV16 and HPV18 are the most common causes of HPV-mediated cancers. Among the over 200 known types of HPV, 13 in the Alphapapillomavirus genus are high-risk, or oncogenic [41, 42]. These include HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 66 [41]. Several other types have been defined as “possibly” carcinogenic [43]. Cervical cancer accounts for 87% of the 610,000 HPV-mediated cancers worldwide and 57% and 18% of cervical cancers are attributable to HPV16 and HPV18, respectively [44]. HPV16 causes 82% of HPV-associated head and neck squamous cell carcinomas [45]. In the USA, HPV16 and HPV18 account for 86% of HPV-mediated OPCs [46].

High-Risk HPV Life Cycle and Pathogenesis

A cursory understanding of the HPV life cycle and pathogenesis provides a basis for understanding the (onco)viral antigen targets of HPV vaccines. A microwound in the epithelium exposing the basal lamina is thought to be a necessary precursor to HPV infection [47]. Virus particles consisting of viral DNA and two capsid proteins (L1, L2) access the basal lamina [47]. Basal epithelial cells internalize the virus, and the viral genome is transferred to the cell nucleus. These infected basal epithelial cells constitute a perpetual reservoir of HPV infection [47]. They divide and generate HPV-infected daughter cells which then migrate towards the cell surface.

The viral life cycle tracks with stages of epithelial cell migration. “Early” in its life cycle, the viral genome expresses six early, or “E,” proteins. E1, E2, E4, E5, E6, and E7 facilitate genome maintenance, cell proliferation, and genome amplification in the lower and middle epithelial layers [47]. In high-risk HPV types, E6 and E7 are oncoproteins which play a major role in determining the disease phenotype [47]. “Late” in its life cycle, the viral genome expresses two late, or “L,” proteins. L1 and L2 constitute the major and minor capsid proteins, respectively. Along with E4, they facilitate virus assembly and release in the upper epithelial layers [47].

Tumor-Specific Antigens: Prophylactic and Therapeutic HPV Vaccine Targets

L1 is the target of current prophylactic HPV vaccines and L1 and L2 serve as potential targets of next-generation vaccines [48]. L1 major capsid proteins self-assemble into highly immunogenic, inert, L1 virus-like particles (VLPs) that resemble the conformation of authentic virions [49–51]. For example, the nonavalent vaccine Gardasil consists of VLPs made of L1 from HPV types 6, 11, 18, 31, 33, 45, 52, and 58, along with the adjuvant, amorphous aluminum hydroxyphosphate sulfate (AAHS). These vaccines generate a robust, durable, neutralizing IgG antibody response and are extremely effective at protecting patients against new HPV infections and corollary development of HPV-mediated cancers [51–53]. According to high-quality phase III trial data, they are not effective against prevalent infections and do not accelerate their clearance [54]. This is presumably because L1 proteins are not expressed early in the viral life cycle; hence, the reservoir of infected basal epithelial cells remains unaffected by the vaccine-induced immune response.

To date, therapeutic vaccines for HPV-mediated tumors have largely targeted E6- and/or E7-based antigens of the HPV16 and/or HPV18 genotypes. The modest efficacy of these vaccines has prompted investigators to consider targeting additional tumor antigens (e.g., E1, E2), and other high-risk HPV genotypes. For example, researchers are investigating the efficacy of a viral vector vaccine expressing conserved regions from all six early proteins from five high-risk genotypes [55].

Foundational Concepts in Therapeutic Cancer Vaccine Immunology

Effective therapeutic cancer vaccines leverage both innate and adaptive immunity. Innate immunity is a rapid, antigen-independent, and nonspecific response to a foreign substance that lacks immunologic memory. A key feature of innate immunity is its ability to recognize conserved features of pathogens using host pattern recognition receptors (PRRs). As described above, TLR ligands are a type of vaccine adjuvant that bind PRRs, activate innate immunity, and polarize the adaptive immune response towards cellular or humoral immunity.

Adaptive immunity is an adaptable, antigen-specific response to a foreign substance (e.g., cancer) that involves immunological memory and is mediated by T and B cells. Adaptive immunity is comprised of cell-mediated immunity and humoral immunity. Therapeutic cancer vaccines primarily aim to kill cancer cells by stimulating cellular immunity. This involves antigen-mediated activation of cytotoxic T cells (CTLs), natural killer (NK) cells, macrophages, and release of cytokines and chemokines. The activated CTLs and NK cells then have the capacity to directly kill tumor cells.

Humoral immunity is an antibody-mediated immune response and plays a secondary role in therapeutic cancer vaccination. Tumor antigen is an antibody generator. Antibodies may bind to tumor antigen and (partially) inactivate tumor cells by blocking their ability to bind host cell receptors, promote tumor cell ingestion and destruction by phagocytes, and activate the complement cascade.

In Fig. 1, we describe the immune response to the spectrum of therapeutic HPV-mediated cancer vaccines.

Therapeutic HPV-Mediated Cancer Vaccine Trial Results: from Past to Present

Overview

To identify relevant manuscripts and clinical trials, we searched clinicaltrials.gov and pubmed.gov, and performed a bibliographic review in November 2021. A systematic, comprehensive literature review was not undertaken for this study; therefore, certain vaccines may not have received due representation.

We describe representative, early vaccines in Appendix Table 3. Next, we review evidence of vaccine efficacy in populations with pre-malignant and malignant disease, respectively (Appendix Table 4; Table 1). Finally, we discuss recently completed, or ongoing, therapeutic vaccine trials evaluating common and uncommon vaccines, respectively (Table 2; Appendix Table 5). Considering the intended reader, we only discuss trials with clinical results. Throughout the below content, we highlight at least one vaccine from each major antigen delivery system category.

Table 3.

Selected early landmark therapeutic vaccine trials for HPV-mediated premalignancies and malignancies

Antigen delivery system category, vaccine, and PMID identifier	Year	Journal	No. of citations*	Phase	N	Eligibility/enrolled	Adjuvant	Clinical and other notable outcomes
Small nucleic acids GX-188E ([DNA plasmid encoding HPV16 and 18 E6/E7 fusion protein] + FLT3L [Fms-like tyrosine kinase-3 ligand])
25354725 [59]	2014	Nat Commun	92	I	9	CIN3	IL-12#	7/9 with complete lesion regression and viral clearance within 36 weeks of follow-up
Viral vector TA-HPV (tissue-antigen-HPV: recombinant vaccinia virus expressing HPV16/18 + E6/7 proteins)
8684105 [56•]	1996	Lancet	111	I/II	8	Invasive CC	-	2/8 disease-free at 15 and 21 months, respectively
Bacterial vector ADXS11-001 (ADXS-HPV; axalimogene filolisbac [AXAL]; Lm-LLO-E7; live attenuated Listeria monocytogenes encoding HPV 16 E7 and tLLO)
19389451 [60]	2009	Vaccine	145	I	15	A/R CC	tLLO#	Flu-like syndrome in 100% patients, grade 3 AEs in 40% of patients; no grade 4/5 AEs; 1/15 with partial response
Peptides ISA101 (HPV16 E6/E7-SLPs [nine E6 SLPs, four E7 SLPs)
19890126 [58•]	2009	N Engl J Med	406	II	22	HPV16 + VIN3	Montanide® ISA-51	Objective clinical response in 79% of patients (n = 15/19) including complete response in 47% (n = 9/19) at 12 months
Protein(s) TA-CIN (tissue-antigen CIN; HPV16 L2/E6/E7 fusion protein)
20234368 [57]	2010	Br J Cancer	98	II	19	VIN2/3	Imiquimod 5% cream	Complete regression of VIN in 58% (n = 11/19) patients at 20-weeks

*Citation number per pubmed.gov, as of 09/4/2022

Table 4.

Results of selected randomized, double-blind, placebo-controlled trials evaluating therapeutic vaccines for HPV-mediated premalignancies

Antigen delivery system category, vaccine, and PMID identifier	Phase	Sample size, distribution, outcome analysis	Dose, type (site), schedule (wks)	Eligibility/enrolled	Adjuvant	Primary and/or secondary clinical (or other) outcomes
Small nucleic acids
VGX-3100 [DNA plasmid encoding HPV16 and 18 E6/E7 genes] with electroporation
26386540 [61••]	IIb	VGX-3100: ITT: 125; PP: 107 Placebo: ITT: 42; PP: 36	6 mgs; 0, 4, 12; IM + EP	HPV16/18 + CIN2/3	EP	Regression to CIN1 or normal pathology at 36 weeks: VGX-3100: 49.5%; placebo: 30.6%, p = 0.034; Concomitant histopathological regression and viral clearance: VGX-3100: 40.2%, placebo: 14.3%, p = 0.003
ZYC101a (DNA plasmid encapsulated in biodegradable poly microparticles encoding segments of HPV16/18 E6/E7 proteins)
14754702 [62]	II	100 mcg: ITT: 53, mITT: 37 200 mcg: ITT: 58, mITT: 49 Placebo: ITT: 50; mITT: 41	100- and 200 mcgs; IM (lateral quadriceps); 0, 3, 6	HPV + CIN2/3, no treatment for cervical dysplasia in the last year, ≤ 2 cervical quadrants involved	-	Histopathologic resolution/regression to ≤ CIN1 based on surgical excisional conization at 6 months: ZYC101a group: 43%, placebo: 27%, p = 0.12; (women < 25 years-old: ZYC101a group: 70%, placebo: 23%, p = 0.007)
Viral vector TG4001 (Tipapkinogen Sovacivec [TS]; attenuated, recombinant MVA [modified vaccinia virus Ankara] coding for IL-2, HPV16 E6/E7)
30955915 [63]	II	TS: ITT: 136; mITT: 129 (55 HPV16 monoinfection) Placebo: ITT: 70; mITT: 63 (27 HPV16 monoinfection)	NR; SQ (thigh); 0, 1, 2	CIN2/3, single or multiple HR-HPV infections; no prior ablative/excisional therapy	MVA, IL-2#	Complete histologic resolution at 6 months in patients with HPV16 monoinfection: TS: 18% (95% CI: 8–28%), placebo: 4% (95% CI: 0–11%); complete histologic resolution at 6 months in patients with any hr-HPV: TS: 24%, placebo: 10%, p < 0.05; regression to ≤ CIN1 at 6 months with any hr-HPV: TS: 36%, placebo: 21%, p < 0.05; viral DNA clearance superior with TS compared to placebo (p < 0.01)
Peptide HPV16 L1E7 CVLP (CVLP [chimeric virus-like particle]; truncated HPV16 L1 protein fused to truncated HPV16 E7 protein)
17721997 [64]	NR	CVLP: 75 mcg: ITT: 14; mITT: 12 CVLP: 250 mcg: ITT: 12; mITT: 11 Placebo: ITT: 13; mITT: 12	75- and 250 mcgs; SQ (upper arm); 0, 2, 6, 12	HPV16 monoinfected CIN2/3; no prior therapy	-	Histopathologic regression to ≤ CIN1 at 24 weeks: CVLP: 39%, placebo: 24%, not significantly different; HPV16 DNA infection clearance at 24 weeks: CVLP: 12%, placebo: 0%, not significantly different

CIN cervical intraepithelial neoplasia, NR not reported

Table 1.

Selected therapeutic vaccines for HPV-mediated malignancies with published, trial-based data

Antigen delivery system category, vaccine, and PMID identifier	Phase	N	Eligibility/enrolled	Adjuvant	Other therapies	Primary and secondary clinical and other outcomes
Small nucleic acids
GX-188E ([DNA plasmid encoding HPV16 and 18 E6/E7 fusion protein] + FLT3L [Fms-like tyrosine kinase-3 ligand])
33271094 [65]	II	36	A/R, inoperable HPV16/HPV18 + CC	EP, FLT3L	Concurrent pembrolizumab	At 24 weeks, ORR: 42% (95% CI: 23–63); CRR: 15%, PRR: 27%; median follow-up 6.2 months (IQR: 3.5–8.1 months)
MEDI0457/INO-3112 (VGX-3100 [DNA plasmid encoding HPV16 and 18 E6/E7 genes] with electroporation + INO-9012 [DNA plasmid encoding IL-12])
32151670 [68]	I	10	Persistent/recurrent cervical cancer after CRT	EP, IL-12	-	Any treatment-related AEs were grade 1; 8/10 patients with detectable cellular or humoral immune responses against HPV antigens
Bacterial vector
ADXS11-001 (ADXS-HPV; axalimogene filolisbac [AXAL]; Lm-LLO-E7; live attenuated Listeria monocytogenes encoding HPV 16 E7 and tLLO)
29538258 [66]	II	109	Recurrent/refractory cervical cancer following prior chemotherapy and/or radiotherapy	tLLO	ADXS11-001 alone or with cisplatin	Median OS: ADXS11-001: 8.3 months; 95% CI, 5.9–10.5 months; ADXS11-001 + cisplatin: 8.8 months; 95% CI, 7.4–13.3 months. Best ORR: ADXS11-001 alone: 17%; ADXS11-001 + cisplatin: 15%
29722659 [72]	I	10	Untreated, invasive, anal canal SCC	tLLO	ADXS11-001 administered as neoadjuvant and adjuvant therapy with concurrent chemoradiation	CRR: 100% among 9 patients completing treatment; rate of grade 3 AEs associated with ADXS11-01: 22%
32341753 [67]	II	36	R/M anorectal SCC not amenable to curative surgery	tLLO	-	ORR: 3.4%; rate of stable disease: 20.7%; 6-month PFS: 15.5%; median PFS: 2.0 months; OS: 12.6 months; rate of grade 3 AEs: 28%; rate of grade 4 AEs: 3%
32641240 [69]	II	50	Metastatic CC s/p curative treatment + ≥ 1-line(s) of systemic chemotherapy and/or biologic therapy	tLLO	-	Any AEs: 98%; rate of grade 3 AEs: 38%; grade 4 AEs: 4% (lung infection/sepsis; hypotension/cytokine release); OS at 12-months: 38%; median OS 6.1 months (95% CI: 4.3–12.1 months); medians PFS 2.8 months; 2% PRR, 10% stable disease
Peptides
ISA101 (HPV16 E6/E7-SLPs [nine E6 SLPs, four E7 SLPs)
23557172 [74]	II	20	Incurable R/M HPV16 + gynecologic cancers (16 CCs, 2 VaCs, 2 ACs)	Montanide® ISA-51	-	ORR: 0%; median OS: 12.6 months; immune response identified in 11/13 patients
30267032 [70]	II	24	Incurable HPV16 + cancers (22 OPCs, 1 CC, 1 AC)	-	Concurrent nivolumab	ORR: 33% (90% CI: 19–50%); CRR: 8%, PRR: 25%; median duration of response: 10.3 months; median PFS: 2.7 months; median OS: 17.5 months
35193933 [73]	“	“	(Longer-term data of the above trial)	“	“	ORR: 29%; median OS of 15.3 months and 2-year OS rate of 33%. Higher expression of immune, inflammatory, and interferon-signaling pathway genes were correlated with clinical response
P16-37–63 (p16INK4a 27-amino acid peptide fragment)
26949913 [71]	I/IIa	26	A/R HPV + cancers (17 CCs, 7 OPCs, 1 VuC, 1 AC)	Montanide® ISA-51 VG	-	Patients experienced grade I AEs only (CTCAE); immune response identified in 17/20 patients; ORR: 0% median follow-up 5.6 months; median PFS 3.5 months, median OS 11.9 months
GL-0810 (HPV16 E7 peptides linked to a “penetrin” peptide sequence facilitating translocation to the ER + GA [Trojan peptide-based vaccine])
25537079 [75]	I	9	R/M HPV16 + HNSCC	Montanide® ISA-51 VG + GM-CSF		Grade 1 toxicity: 7/9; grade 2 toxicity: 3/9; T cell and antibody response in 4/9 patients [4/5 who received all 4 vaccinations; ORR: 0%; PFS: 80 days; OS: 196 days
Autologous cell-based
BVAC-C (autologous B cells and monocytes transfected with recombinant HPV16/18 E6 and E7 genes)
31948126 [76]	I	11	R/M HPV16/18 cervical cancer	α-Galactosyl ceramide	-	ORR: 11% (95% CI: 0–32%); 56% achieved stable disease (95% CI: 23–88%); median OS: 12 months

A advanced, AE adverse event, CC cervical cancer, CI confidence interval, CR complete response, CTCAE Common Terminology Criteria for Adverse Events, ER endoplasmic reticulum, GA Golgi apparatus, GM-CSF granulocyte–macrophage colony-stimulating factor, HNSCC head and neck squamous cell carcinoma, IQR interquartile range, ORR overall response rate OS overall survival, PRR partial response rate, R/M recurrent/metastatic, SCC squamous cell carcinoma

Table 2.

Selected therapeutic vaccines for HPV-mediated premalignancies and malignancies under active or completed trial-based investigation, without published results

Antigen delivery system category and vaccine	Phase	N	Eligibility	Adjuvant	Other therapies	(Projected) trial end date
Small nucleic acids
MEDI0457/INO-3112 (VGX-3100 [DNA plasmid encoding HPV16 and 18 E6/E7 genes] with electroporation + INO-9012 [DNA plasmid encoding IL-12])
NCT03439085	II	77	R/M HPV16/18 + cancers	EP, IL-12#	Concurrent durvalumab	Dec 2022
NCT02172911	I/II	10	Primary CC s/p CRT; R/M CC	EP, IL-12#	Curative intent: INO-3112 as adjuvant; R/M: INO-3112 alone	Sept 2017
NCT03162224	I/IIa	35	R/M HPV + HNC	EP, IL-12#	Concurrent durvalumab	March 2021
NCT02163057	I/IIa	22	HPV + HNC	EP, IL-12#	INO-3112 followed by surgery vs CRT	January 2017
NCT03185013	III	201	HPV 16/18 + CIN2/3	EP	VGX-3100 only	April 2021
NCT03721978	III	203	HPV 16/18 + CIN2/3	EP	VGX-3100 only	Sept 2022
NCT03603808	II	80	HIV + patients with anal HPV16/18 + HSIL	EP	VGX-3100 only	Aug 2022
NCT00685412	I	18	CIN II/III patients after surgery/ablation	EP	VGX-3100 only	March 2011
NCT03180684	II	36	VIN 2/3	EP	Imiquimod	December 2020
GX-188E ([DNA plasmid encoding HPV16 and 18 E6/E7 fusion protein] + FLT3L [Fms-like tyrosine kinase-3 ligand])
NCT03444376	Ib/II	60	Advanced, unresectable HPV16/18 + CC	EP, FLT3L#	Concurrent pembrolizumab	Dec 2023
NCT02596243	III	134	HPV 16/18 + CIN 2/3	EP, FLT3L#	-	Aug 2018
NCT02139267	II	72	HPV16/18 + CIN 3	EP, FLT3L#	-	March 2016
VB10.16 (DNA plasmid encoding recombinant protein consisting of 3 modules: inactivated HPV16 E6/E7 protein, human chemokine MIP-1α, linked via dimerization module derived from human IgG3)
NCT04405349	IIa	50	R/M HPV16 + CC ineligible for other therapies	MIP-1α#	Concurrent atezolizumab	Jan 2023
NCT02529930	I/II	34	HPV16 + cervical HSIL (CIN 2/3)	MIP-1α#	-	Jan 2019
pNGVL4aCRTE6E7L2/ pNGVL4aCRTE6E7(detox) (DNA plasmid encoding calreticulin, HPV16 E6/E7/L2 proteins)
NCT04131413	I	48	HIV + HPV16 + CIN2/3	-	-	December 2024
NCT00988559	I	132	HPV16 + CIN 2/3	-	± Imiquimod	July 2016
BNT113 (mRNA encoding HPV16 E6 and E7 proteins encapsulated within liposomes)
NCT04131413	II	285	Unresectable, R/M HPV16 +, PD-L1 + HNSCC	Liposomes	Pembrolizumab alone versus pembrolizumab with BNT113	May 2025
NCT03418480	I/II	44	Previously treated HPV16 + HNSCC; advanced HPV16 + mediated cervical, head and neck, anal, or penile cancer	Liposomes		Oct 2024
Viral vector (see combination vaccine category: TA-HPV, Ad-E6E7, MG1-E6E7)
Bacterial vector
ADXS11-001 (ADXS-HPV; axalimogene filolisbac [AXAL]; Lm-LLO-E7; live attenuated Listeria monocytogenes encoding HPV 16 E7 and tLLO)
NCT02002182	II	15	Resectable HPV + OPC	tLLO#	ADXS11-001 followed by primary surgery	Aug 2023
NCT02399813	II	51	Persistent/recurrent anorectal SCC s/p at least one treatment regimen	tLLO#	-	May 2019
NCT02853604	III	450	High-risk locally advanced CC after CRT	tLLO#	ADXS11-001 as adjuvant after definitive CRT	October 2024
Peptides
ISA101/101b (HPV16 E6/E7-SLPs [both ISA101 and 101b have nine E6 SLPs; ISA101 has four E7 SLPs while ISA101b has three E7 SLPs])
NCT02128126	I/II	93	A/R CC	± IFNα-IIb	ISA101/101b + neoadjuvant carboplatin + paclitaxel ± bevacizumab	Aug 2018
NCT04646005	II	105	R/M HPV16 + CC	-	ISA101b + concurrent cemiplimab	Oct 2024
NCT03258008	II	27	Incurable HPV16 + OPC	-	ISA101b + concurrent utomilumab	June 2022
NCT04369937	II	50	Primary iIntermediate risk HPV + OPC	-	ISA101b concurrent pembrolizumab + IMRT + cisplatin	June 2024
NCT04398524	II	86	R/M HPV16 + OPC w/ progression on ICIs	-	ISA101b concurrent cemiplimab	Nov 2024
NCT01923116	I/II	40	HIV + men with HPV16 +, grade 2–3 AIN; CD4 count > 350/ul; local treatment-resistant	± IFN-α	-	Dec 2017
PDS0101 (nanoparticle-based cationic lipid R-DOTAP encapsulates six HPV16 + E6/E7 peptides; R-DOTAP elicits a cellular immune response)
NCT04580771	II	35	Primary, LA CC	R-DOTAP#	CRT + concurrent and adjuvant PDS0101	March 2024
NCT02065973	I	12	Hr-HPV + CIN 1	R-DOTAP#	-	Dec 2015
PepCan (4 peptides covering HPV16 E6)
NCT03821272	I/II	20	HNSCC	Candida	-	December 2025
NCT02481414	II	125	HPV16 + cervical HSIL (CIN 2/3)	Candida	-	June 2022
Autologous cell-based
SQZ-PBMC-HPV (peripheral blood mononuclear cells manufactured with immunogenic HPV16 epitopes)
NCT04084951	I	200	HLA-A*02 + patients with LA/R/M HPV16 + cancers		Concurrent atezolizumab OR ipilimumab OR nivolumab OR nivolumab + ipilimumab	November 2022
NCT04892043	I	72	HLA-A*02 + patients with LA/R/M HPV16 + cancers	-	Alone OR with concurrent: nivolumab OR ipilimumab OR nivolumab + ipilimumab	April 2024
BVAC-C (B cells and monocytes transfected with E6/E7 gene of HPV)
NCT02866006	I/II	32	Multiple metastatic progressive or recurrent HPV16/18 + CC	-	± Concurrent topotecan	December 2022
NCT04800978	II	37	HPV16/18 + CC failure after first-line platinum-based chemotherapy		Concurrent durvalumab	August 2024
Heterologous prime-boost
PVX-2 pBI-1 (small nucleic acid, prime vaccine: DNA plasmid encoding both signal peptide pNGVL4a-Sig [a detox form of HPV16 E7] AND HSP70) +  TA-CIN (boost, protein vaccine)
NCT03911076	II RCT	122	HPV16 + ASC-US, ASC-H, LSIL of cervix	-	Randomized to PVX-2 versus placebo	Jan 2024
pBI-1 (prime vaccine) +  TA-HPV (tissue-antigen-HPV, boost, viral vector vaccine: recombinant vaccinia virus expressing HPV16/18 + E6/7 proteins)
NCT00788164	I	75	HPV16 + CIN3	± imiquimod	pBI-1 + TA HPV OR imiquimod OR pBI-1 + TA HPV + imiquimod	Dec 2022
TheraT® vectors HB-201 attenuated arenavirus LCMV encoding inactivated HPV16 E6/E7 fusion protein +  HB-202 attenuated arenavirus encoding inactivated HPV16 E6/E7 fusion protein (administered with neoadjuvant chemotherapy prior to surgery)
NCT05108870	I/II	98	HPV + OPSCC	-	HB-201/HB-202 and carboplatin and paclitaxel ± surgery vs RT vs CRT	January 2026
NCT04180215	I/II	100	R/M HPV + cancers	-	-	June 2022

Trials in patients with HPV-mediated premalignancies part of, or encoded for, in the vaccine. ASC-US atypical squamous cells of undetermined significance, ASC-H atypical squamous cells – cannot exclude high-grade squamous intraepithelial lesion, CC cervical cancer, CIN cervical intraepithelial neoplasia, CRT chemoradiation therapy, HLA human leukocyte antigens, HPV human papillomavirus, Hr high risk, HSP heat shock protein, ICI immune checkpoint inhibitor, LA locally advanced, LSIL low-grade squamous intraepithelial lesion, OPC oropharyngeal cancer, R-DOTAP R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride, R/M recurrent/metastatic, SLPs synthetic long peptides, tLLO truncated Listeriolysin O

Table 5.

Other selected therapeutic vaccines for HPV-mediated premalignancies and malignancies under active or completed trial-based investigation, without published results

Antigen delivery system category and vaccine	Clinicaltrials.gov identifier
Small nucleic acids
ISA201 (two HPV16 E6 SLPs) + (Amplivant® [TLR2-L])	NCT02821494
HARE-40 (HPV anti-CD40 RNA vaccine)	NCT03418480
Viral vector
PRGN-2009 (gorilla adenovirus encoding HPV16/18 E6/E7 proteins) ± M7824	NCT04432597
Vvax001 (attenuated Semliki Forest Virus [SFV] encoding E6/E7 proteins)	NCT03141463
Peptides
P16-37–63 (p16INK4a 27-amino acid peptide fragment) + Montanide® ISA-51 VG	NCT02526316
DPX-E7 (synthetic HPV16 E7 peptide consisting of amino acids 11–19)	NCT02865135
Protein
TA-CIN (tissue-antigen CIN; HPV16 L2/E6/E7 fusion protein)	NCT02405221
TVGV-1 (HPV16 E7 bacterial exotoxin fusion protein) + GPI-0100	NCT02576561
ProCervix (two recombinant adenylate cyclase proteins, CyaA-HPV 16E7 and CyaA-HPV 18E7) + Aldara (5% imiquimod)	NCT01957878
Autologous cell-based
DCs loaded with HPV16/18 E6/E7, injected into adjacent lymph node × 6	NCT03870113
Peripheral blood mononuclear cells (PBMC) (antigen-presenting cells) treated in vitro with sargramostim (GM-CSF) pulsed with HPV16 E6 or E7, administered IV	NCT00019110
Heterologous prime-boost
Ad-E6E7 (prime, viral vector vaccine: recombinant adenovirus encoding mutant, inactive HPV E6/E7 proteins) +  MG1-E6E7 (boost, viral vector vaccine: recombinant, attenuated oncolytic rhabdovirus Maraba encoding HPV E6/E7 proteins; virus preferentially invades tumor cells, induces E6/E7 expression, lyses tumor cells, and invades adjacent tumor cells)	NCT03618953
VTP-200 ChAdOx1-HPV recombinant, attenuated, chimpanzee adenovirus encoding conserved elements of HPV16/18/31/52/58 E1/E2/E4/E6/E7 proteins +  MVA-HPV (boost) modified, attenuated vaccinia virus Ankara strain (MVA) encoding conserved elements of HPV16/18/31/52/58 E1/E2/E4/E6/E7	NCT04607850

Normal font: Trial in patients with HPV-mediated malignancies. Italicized font: Trial in patients with HPV-mediated premalignancies. CRT human calreticulin, a heat shock protein, LCMV lymphocytic choriomeningitis virus, M7824 (bintrafusp alfa) bifunctional fusion protein anti-PD-L1 human monoclonal antibody bound to extracellular domain of human TGF-β-receptor II, LLR2-L toll-like receptor 2 ligand

Early Landmark Trials

Appendix Table 3 highlights early trials evaluating representative therapeutic vaccines for HPV-mediated precancers and cancers [56•, 57, 58•, 59, 60]. There are several notable findings. To our knowledge, tissue-antigen HPV (TA-HPV) was the first therapeutic vaccine tested in humans to treat HPV-mediated disease [56• ]. In this viral vector vaccine, recombinant vaccinia virus was engineered to express HPV16 E6 and E7 proteins, along with HPV18 E6 and E7 proteins, and administered to cervical cancer patients [56• ]. Second, while outcomes of therapeutic vaccination were underwhelming for patients with invasive cancer (including TA-HPV) [56•, 60], outcomes were more favorable for patients with precancer [57, 58•, 59]. For example, the preliminary success of the first ISA101 trial in patients with HPV16 + vulvar intraepithelial neoplasia (VIN)-3 is underscored by its high-impact publication [58• ]. ISA101 is a peptide-based vaccine comprised of nine HPV16 E6 synthetic long-chain peptides (SLPs) and four HPV16 E7 SLPs [58• ]. Third, this is an emerging discipline. The outcomes of most early, therapeutic HPV vaccine trials were published within the last 15 years.

Randomized, Double-Blind, Placebo-Controlled Trials in Cervical Intraepithelial Neoplasia Patients

Several trials have evaluated therapeutic HPV vaccines in patients with cervical and anal intraepithelial neoplasia patients. However, only a handful are of high quality (see Appendix Table 4) [61••, 62–64]. Most of these randomized (blinded), controlled trials demonstrate that therapeutic HPV vaccination either trends towards efficacy or is effective in patients with cervical intraepithelial neoplasia (CIN) [61••, 62–64]. Notably, only the small nucleic acid vaccine VGX-3100 was significantly more effective than placebo according to its primary study outcome. Significantly more vaccinated patients (49.5%) than control patients (30.6%; p= 0.034) exhibited histopathological regression from CIN 2–3 disease to CIN 1 or normal pathology at 36 weeks [61••]. VGX-3100 is a DNA plasmid encoding HPV16 E6 and E7 genes, as well as HPV18 E6 and E7 genes. VGX-3100 is co-administered intramuscularly with electroporation [61••]. During electroporation, an electrical current transiently disrupts cell membrane integrity, facilitating DNA uptake in host cells [61••].

Phase I–II Trials in Patients with HPV-Mediated Malignancies

Conversely, clear evidence of therapeutic vaccine efficacy in patients with advanced, recurrent, or metastatic HPV-mediated malignancies is limited (Table 1) [65–76]. These trials exhibit a few significant findings. First, therapeutic vaccination alone was often unsuccessful. For example, all three peptide-based vaccines exhibited an overall response rate of 0% [71, 74, 75].

Second, in the rare circumstances when vaccine efficacy was identified, the degree of efficacy was limited [66, 67, 69, 76]. In a phase I trial of nine evaluable patients with recurrent or persistent cervical cancer treated with BVAC-C, an APC-based vaccine, the overall response rate was 11%, and 56% exhibited stable disease for 4.2–11 months [76]. Preparation and administration of BVAC-C requires apheris, PBMC collection, and isolation of B cells and monocytes. These cells are transduced with recombinant HPV16 E6 and E7 genes, as well as HPV18 E6 and E7 genes, using an adenovirus vector. The cells are incubated with α-galactosyl ceramide, a natural killer T cell ligand. These recombinant, autologous APCs are then harvested, prepared, and administered back to patients via intravenous injection.

ADXS11-001 alone also exhibited limited efficacy in patients [66, 67, 69]. Axalimogene filolisbac (ADXS-HPV) is a live, attenuated, recombinant, therapeutic vaccine that uses Listeria monocytogenes (Lm) as a bacterial vector. Native Listeria monocytogenes is an intracellular bacterium that uses listeriolysin O (LLO) and phospholipase C to escape phagosomes and enter the host cell cytoplasm. ADXS-HPV secretes an adjuvant-antigen fusion protein consisting of a truncated LLO fragment fused to a full-length HPV16 E7 peptide (tLLO-HPV16 E7). In a trial of 50 recurrent, metastatic cervical cancer patients who failed first-line systemic therapy, only 6% of patients exhibited a response to vaccination [69]. One patient with diffuse, metabolically avid retroperitoneal adenopathy exhibited a durable, complete response lasting 34 months at last follow-up [69]. However, this limited success was partially offset by concerns regarding treatment toxicity [69]. In the trial, 38% of patients experienced a grade 3 adverse event and 4% experienced a grade 4 adverse event [69].

Third, although a proportion of patients in combination trials responded to therapy, the degree to which efficacy is attributable to therapeutic vaccination is unknown [65, 70]. In the ISA101 + nivolumab [70] and GX-188E + pembrolizumab [65] trials, complete response rates ranged from 8 to 15% and overall response rates ranged from 33 to 42%, respectively [65, 70]. However, these outcomes substantially overlap with those of trials evaluating ICIs alone in similar populations [17], suggesting that vaccination may have conferred little to no benefit.

Ongoing, Recently Completed, or Recently Closed Therapeutic Vaccine Trials Without Published Results for HPV-Mediated (Pre)Malignancies

Since the primary barriers to vaccine efficacy in HPV-mediated malignancies are unknown, investigators have employed a shotgun approach to evaluate myriad, diverse, next-generation vaccines. In Table 2 and Appendix Table 5, we describe ongoing, recently completed, or recently closed vaccine trials for HPV-mediated malignancies and premalignancies. The results of these trials have not yet been published. Table 2 describes vaccines undergoing testing in multiple trials or phase II trials. Appendix Table 5 lists vaccines undergoing testing in single, smaller trials. Below, we synthesize and highlight several noteworthy findings from these collective trials.

The Challenge of Therapeutic HPV Vaccine Development

Among the many new trials featured in Table 2, many older trials with projected end dates from 2011 to 2019 have still not published their results. Trial investigators may not have prioritized dissemination of their findings due to negative or null results.

ADXS-HPV vaccine trial progress underscores the challenge of therapeutic vaccine development. To our knowledge, this therapeutic vaccine has been the only vaccine to undergo phase III trial investigation (AIM2CERV) in patients with HPV-mediated malignancies. Despite this, FDA-mediated concerns about treatment toxicity, as well as product chemistry, manufacturing, and controls, have recently dominated discussions about this vaccine [77–80]. Advaxis, the company that produces ADXS-HPV, has abruptly discontinued at least two ADXS-HPV trials. They specified that these decisions stemmed from financial concerns, not safety concerns or concerns about trial results [81]. Although the company continues to champion this product [82], we are not aware of any open ADXS-HPV trials that are actively recruiting patients.

Enthusiasm for New Adjuvants

The current wave of new trials has exhibited a common interest in testing new adjuvants. Some established vaccines have undergone adjuvant upgrades. MEDI0457 consists of VGX-3100 paired with INO-9012, a DNA plasmid encoding IL-12, which directs a cell-mediated immune response [68]. ISA201 consists of two HPV16 E6 SLPs paired with Amplivant®, a synthetic toll-like receptor-2 (TLR2) ligand [83, 84]. TLR2 ligand enhances SLP presentation to antigen-presenting cells (APCs), SLP processing, and APC activation [83, 84].

Other, less established vaccines are also testing novel adjuvants. The peptide-based vaccine PDS0101 uses the cationic lipid enantiomer R-1,2-dioleoyl-3-trimethylammonium-propane (R-DOTAP) to encapsulate and deliver its HPV16 E6 and E7 peptides. According to preclinical studies, R-DOTAP also activates TLR7 and TLR9, stimulating type 1 interferon production and a potent CD8 T cell response [85].

Use of Combination Therapy for HPV-Mediated Malignancies

Considering the limited efficacy of therapeutic vaccination alone for HPV-mediated malignancies to date, many new vaccine trials have paired vaccination with an ICI. For example, the phase II, AHEAD-MERIT trial aims to evaluate pembrolizumab monotherapy versus pembrolizumab with BNT113, an mRNA-based vaccine, as first-line therapy in 285 patients with unresectable recurrent or metastatic HPV16 +, PD-1-positive, head and neck squamous cell carcinoma [86]. BNT113 consists of mRNA encoding HPV16 E6 and E7 oncoproteins encapsulated within liposomes [86].

An ongoing phase II trial is evaluating PDS0101 in combination with M9241 (an immunocytokine) and bintrafusp alfa (a bifunctional fusion protein composed of the transforming growth factor β (TGF-β) receptor and an ICI) for patients with HPV16 + head and neck, cervical, anal, and vaginal cancers. Among 18 patients, the overall response rate was 55.6% and among six ICI-naïve patients, the ORR was 83.3% [87••].

A handful of trials for primary cancer patients have applied traditional, first-line therapy with therapeutic vaccination as neoadjuvant, concurrent, and/or adjuvant treatment.

Heterologous Prime-Boost Vaccines

In the heterologous prime-boost approach, the prime and booster vaccines are unique (Tables 4 and 5) [88]. The TheraT® viral vectors HB-201 and HB-202 represent an important example of this approach. HB-201 consists of attenuated, recombinant lymphocytic choriomeningitis (LCMV) encoding an inactivated HPV16 E6 and E7 fusion protein. HB-202 consists of recombinant Pichinde virus (PICV) encoding the same protein [89]. LCMV and PICV are two different RNA-based arenavirus species within the family Arenaviridae and genus Mammarenavirus. Early phase I results in patients with recurrent/metastatic HPV16 + cancers have been promising [87••]. Immunogenicity may be greater in patients receiving alternating therapy compared to monotherapy (HB-201 alone) [90].

Other Future Directions

Personalized Therapeutic Vaccines

Considering the limited efficacy of therapeutic vaccines that use HPV-specific antigens, personalized, therapeutic vaccines may warrant further investigation. The basis for personalized therapeutic vaccination is that mutations in tumor cell DNA result in the production of novel epitopes of self-antigens (i.e., neoantigens), which can be identified by next-generation sequencing. Neoantigens that are anticipated to elicit an immune response are selected and the vaccine is produced. The weaknesses of this approach include the high cost, time-intensive nature, and challenge of selecting neoantigens that can be presented by antigen-presenting cells in vivo.

GEN-009, a representative neoantigen-based vaccine, was recently evaluated in a phase I/IIa trial in patients with solid tumors, including head and neck squamous cell carcinoma. Early safety, immune response, and efficacy data were encouraging [91].

Need for Novel, Multimodal Therapeutic Approaches

Given the complexity of cancer biology, maximally optimized, therapeutic HPV vaccines are unlikely to cure HPV-mediated malignancies on their own. In their landmark article, “Hallmarks of Cancer: Next Generation,” Hanahan and Weinberg described the eight hallmark, biological capabilities of cancer [92]. Only one involves “avoiding immune destruction.” [92] The other seven hallmarks include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, and deregulating cellular energetics [92]. Genome instability and mutation, as well as tumor-promoting inflammation, are two key enabling characteristics of these hallmarks [92].

Novel, multimodal oncologic approaches that more comprehensively address these diverse hallmarks of cancer will be necessary. Investigators have established biological rationales for pairing immune checkpoint inhibition with virtually all other oncologic therapies, including, but not limited to, therapeutic vaccination [87••, 93, 94], other immunotherapies (e.g., oncolytic virus therapy) [93, 95], cytotoxic chemotherapy [96], and radiotherapy [97]. Evaluation of novel approaches involving three or more therapies, including therapeutic HPV vaccination and immune checkpoint inhibition, appears indicated [87••].

Additionally, most combination trials are evaluating therapeutic HPV vaccines in the locoregionally advanced, recurrent, or metastatic setting. However, there is also a strong biological rationale for therapeutic HPV vaccination, with or without ICIs, in the primary, neoadjuvant setting, followed by standard first-line therapy [98–100].

Conclusion

Despite their limited efficacy to date, therapeutic vaccines for HPV-mediated malignancies retain a strong biological rationale, along with substantial clinical promise. Myriad ongoing trials evaluating diverse antigen delivery systems, adjuvant, prime-boost approaches, and combination therapies are sure to advance the discipline. Combination regimens incorporating therapeutic HPV vaccination, immune checkpoint inhibition, and other therapies (e.g., novel adjuvant[s]) may most effectively harness the power of this therapy.

Funding

Eugene P. Frenkel, M.D., Clinical Scholars Program.

Declarations

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.